15:39 PM
After Medarex (MEDX +89%) fetched a healthy premium from Bristol-Myers Squibb (BMY +3.1%), investors have begun looking at similar companies to see who's next up for bids: Regeneron Pharmaceuticals (REGN +8.8%)? Seattle Genetics (SGEN +5.6%)? Alexion (ALXN +7.6%)? Allos Therapeutics (ALTH +6.9%)? Celldex Therapeutics (CLDX +6.7%)? Dendreon (DNDN +6.6%)?
Comment!
19:37 PM
Bristol-Myers Squibb (BMY) has agreed to acquire Medarex (MEDX) for $16/share in cash - about $2.4B - saying it is gaining proven antibody discovery technology and rights to an immunotherapy the companies developed. Medarex closed +1.5% to $8.40. (BMY earnings preview)
1 Comment